Abstract
The angiotensin II (Ang II) type 1a (AT1a) receptor is expressed on multiple cell types in atherosclerotic lesions, including bone marrow–derived cells and vascular wall cells, and mediates inflammatory and proliferative responses. Indeed, Ang II infusion accelerates atherogenesis in hyperlipidemic mice by recruiting monocytes and by activating vascular wall cells. Here, we investigated the relative roles of AT1a receptors in the bone marrow vs. the vascular wall in Ang II–induced atherogenesis. Apolipoprotein E–knockout (ApoE−/−) mice with or without bone marrow AT1a receptor were generated by experimental bone marrow transplantation using AT1a+/+ or AT1a−/− recipients. In these mice, 28-d Ang II infusion induced significant atherosclerosis in the aorta, and the severity of plaque formation was not affected by the absence of bone marrow AT1a receptor. We then generated AT1a−/−ApoE−/− mice with or without bone marrow AT1a receptor. Ang II–induced plaque formation was blunted irrespective of the presence of bone marrow AT1a receptor. Host AT1a receptor deficiency was found to suppress Ang II–induced reactive oxygen species production. In addition, AT1a receptor deficiency also impaired monocyte chemoattractant protein-1 (MCP-1) and vascular cell adhesion molecule-1 (VCAM-1) expression in the arterial wall 7 d after Ang II initiation. These molecules normally initiate later macrophage-mediated inflammation in the vascular wall. By contrast, AT1a receptor deficiency in the bone marrow did not affect MCP-1–induced monocyte chemotaxis in vitro. In conclusion, AT1a receptors in the host vascular wall, but not in the bone marrow, are essential in Ang II–induced atherogenesis.
Similar content being viewed by others
Article PDF
References
Fox KM : Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–788.
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G : Effects of an angiotensin-converting–enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–153.
Brasier AR, Recinos A 3rd, Eledrisi MS : Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002; 22: 1257–1266.
Dzau VJ : Theodore Cooper Lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001; 37: 1047–1052.
Wassmann S, Czech T, van Eickels M, Fleming I, Böhm M, Nickenig G : Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice. Circulation 2004; 110: 3062–3067.
Daugherty A, Manning MW, Cassis LA : Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E–deficient mice. J Clin Invest 2000; 105: 1605–1612.
Weiss D, Kools JJ, Taylor WR : Angiotensin II–inducedhypertension accelerates the development of atherosclerosisin apoE-deficient mice. Circulation 2001; 103: 448–454.
Ni W, Kitamoto S, Ishibashi M, et al: Monocyte chemoattractantprotein-1 is an essential inflammatory mediator inangiotensin II–induced progression of established atherosclerosis in hypercholesterolemic mice. Arterioscler Thromb Vasc Biol 2004; 24: 534–539.
Kranzhofer R, Browatzki M, Schmidt J, Kubler W : Angiotensin II activates the proinflammatory transcription factornuclear factor-kappaB in human monocytes. Biochem Biophys Res Commun 1999; 257: 826–828.
Tamarat R, Silvestre JS, Durie M, Levy BI : Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways. Lab Invest 2002; 82: 747–756.
Weber H, Taylor DS, Molloy CJ : Angiotensin II inducesdelayed mitogenesis and cellular proliferation in rat aorticsmooth muscle cells. Correlation with the expression of specific endogenous growth factors and reversal by suramin. J Clin Invest 1994; 93: 788–798.
Liu G, Espinosa E, Oemar BS, Lüscher TF : Bimodal effects of angiotensin II on migration of human and rat smooth muscle cells. Direct stimulation and indirect inhibition via transforming growth factor-beta 1. Arterioscler Thromb Vasc Biol 1997; 17: 1251–1257.
Ishibashi M, Egashira K, Zhao Q, et al: Bone marrow–derived monocyte chemoattractant protein-1 receptor CCR2 is critical in angiotensin II–induced acceleration of atherosclerosis and aneurysm formation in hypercholesterolemicmice. Arterioscler Thromb Vasc Biol 2004; 24: e174–e178.
Ishibashi M, Hiasa K, Zhao Q, et al: Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation andremodeling. Circ Res 2004; 94: 1203–1210.
Cassis LA, Rateri DL, Lu H, Daugherty A : Bone marrow transplantation reveals that recipient AT1a receptors arerequired to initiate angiotensin II–induced atherosclerosis and aneurysms. Arterioscler Thromb Vasc Biol 2007; 27: 380–386.
Fukuda D, Sata M, Ishizaka N, Nagai R : Critical role of bone marrow angiotensin II type 1 receptor in the pathogenesis of atherosclerosis in apolipoprotein E deficient mice. Arterioscler Thromb Vasc Biol 2008; 28: 90–96.
Sugaya T, Nishimatsu S, Tanimoto K, et al: Angiotensin II type 1a receptor–deficient mice with hypotension and hyperreninemia. J Biol Chem 1995; 270: 18719–18722.
Inoue S, Egashira K, Ni W, et al: Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E–knockout mice. Circulation 2002; 106: 2700–2706.
Ni W, Egashira K, Kitamoto S, et al: New anti—monocytechemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E–knockout mice. Circulation 2001; 103: 2096–2101.
Nakano K, Egashira K, Ohtani K, et al: Catheter-based adenovirus–mediated anti–monocyte chemoattractant genetherapy attenuates in-stent neointima formation in cynomolgus monkeys. Atherosclerosis 2007; 194: 309–316.
Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW : Angiotensin II stimulates NADH and NADPH oxidaseactivity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141–1148.
Tummala PE, Chen XL, Sundell CL, et al: Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: a potential link between the renin-angiotensin system and atherosclerosis. Circulation 1999; 100: 1223–1229.
Guo J, Van Eck M, Twisk J, et al: Transplantation of monocyte CC-chemokine receptor 2–deficient bone marrow into ApoE3-Leiden mice inhibits atherogenesis. Arterioscler Thromb Vasc Biol 2003; 23: 447–453.
Touyz RM, Yao G, Viel E, Amiri F, Schiffrin EL : Angiotensin II and endothelin-1 regulate MAP kinases through different redox-dependent mechanisms in human vascular smooth muscle cells. J Hypertens 2004; 22: 1141–1149.
Ni W, Zhan Y, He H, Maynard E, Balschi JA, Oettgen P : Ets-1 is a critical transcriptional regulator of reactive oxygen species and p47 (phox) gene expression in response to angiotensin II. Circ Res 2007; 101: 985–994.
Mollnau H, Wendt M, Szocs K, et al: Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 2002; 90: E58–E65.
Egashira K : Molecular mechanisms mediating inflammation in vascular disease: special reference to monocytechemoattractant protein-1. Hypertension 2003; 41: 834–841.
Kitamoto S, Nakano K, Hirouchi Y, et al: Cholesterol-lowering independent regression and stabilization of atherosclerotic lesions by pravastatin and by antimonocyte chemoattractant protein-1 therapy in nonhuman primates. Arterioscler Thromb Vasc Biol 2004; 24: 1522–1528.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Koga, Ji., Egashira, K., Matoba, T. et al. Essential Role of Angiotensin II Type 1a Receptors in the Host Vascular Wall, but Not the Bone Marrow, in the Pathogenesis of Angiotensin II–Induced Atherosclerosis. Hypertens Res 31, 1791–1800 (2008). https://doi.org/10.1291/hypres.31.1791
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.31.1791
Keywords
This article is cited by
-
Qingre Quyu Granule (清热祛瘀颗粒) stabilizes plaques through inhibiting the expression of tenascin-C in patients with severe carotid stenosis
Chinese Journal of Integrative Medicine (2015)
-
Relationship between angiotensin I-converting enzyme insertion/deletion gene polymorphism and retinal vein occlusion
Thrombosis Journal (2014)
-
Genetic Variants of the Renin Angiotensin System: Effects on Atherosclerosis in Experimental Models and Humans
Current Atherosclerosis Reports (2010)